In 2025, CSPC Innovation Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, CSPC Innovation Pharmaceutical has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2025 | 2024 |
|---|---|---|
Total Scope 1 | 11,898.09a | 4,867a |
Total Scope 2 | ||
Unspecified Calculation Method | 243,526.62a | 295,500a |
Total Scope 3 | N/A | N/A |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 38.6047a | 17.9325a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of CSPC Innovation Pharmaceutical amounted to 255,424.71 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of CSPC Innovation Pharmaceutical decreased by 14.96%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2025, the total Scope 1 emissions of CSPC Innovation Pharmaceutical were 11,898.09 metric tons of CO₂ equivalent (tCO₂e).a
Compared to the previous year (2024), CSPC Innovation Pharmaceutical's Scope 1 emissions increased by 144.46%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2025, CSPC Innovation Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 243,526.62 tCO₂e without specifying the calculation method.a
Compared to the previous year (2024), CSPC Innovation Pharmaceutical's Scope 2 emissions (Unspecified Calculation Method) fell by 17.59% in 2025, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.a
In 2025, CSPC Innovation Pharmaceutical reported its Scope 2 emissions using an unspecified methodology.a
In 2025, CSPC Innovation Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 11,898.09 tCO₂e and total revenues of USD 308 millions. This translates into an emissions intensity of 38.6 tCO₂e per millions USD.a
In 2025, CSPC Innovation Pharmaceutical reported a Scope 1 emissions intensity of 38.6 tCO₂e per millions USD. Compared to the peer group median of 20.05, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2025, CSPC Innovation Pharmaceutical ranked 17 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
CSPC Innovation Pharmaceutical is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a